318 related articles for article (PubMed ID: 19472544)
1. [Incretin related agents for treatment of diabetes mellitus].
Miyagawa J; Miuchi M; Nanba M
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):809-16. PubMed ID: 19472544
[No Abstract] [Full Text] [Related]
2. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
3. [The value of incretin based therapies].
Gallwitz B
Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
[No Abstract] [Full Text] [Related]
4. [Incretin-based therapy for treating patients with type 2 diabetes].
Jermendy G
Orv Hetil; 2011 Nov; 152(48):1931-40. PubMed ID: 22071295
[TBL] [Abstract][Full Text] [Related]
5. GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Ahrén B
Curr Diab Rep; 2007 Oct; 7(5):340-7. PubMed ID: 18173966
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
Fakhoury WK; Lereun C; Wright D
Pharmacology; 2010; 86(1):44-57. PubMed ID: 20616619
[TBL] [Abstract][Full Text] [Related]
7. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
8. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
9. Incretin-based therapies in type 2 diabetes: a review of clinical results.
Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
[TBL] [Abstract][Full Text] [Related]
10. Distinguishing among incretin-based therapies. Patient education and self-management.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S28-30. PubMed ID: 20824237
[TBL] [Abstract][Full Text] [Related]
11. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.
Nicolucci A; Rossi MC
Acta Biomed; 2008 Dec; 79(3):184-91. PubMed ID: 19260377
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic use and adverse events of incretin-related drugs].
Ishikawa M; Yamada Y
Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
[No Abstract] [Full Text] [Related]
14. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
Davidson JA; Parente EB; Gross JL
Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):1039-49. PubMed ID: 18820816
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
16. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Garber AJ
Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
[TBL] [Abstract][Full Text] [Related]
17. [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Scheen AJ
Rev Med Liege; 2007 Apr; 62(4):217-21. PubMed ID: 17566392
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Amori RE; Lau J; Pittas AG
JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
[TBL] [Abstract][Full Text] [Related]
19. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Kleefstra N; van Hateren KJ; Houweling ST; Verhoeven S; Kooy A; Goudswaard AN; Bilo HJ
Ned Tijdschr Geneeskd; 2010; 154():A886. PubMed ID: 20298625
[TBL] [Abstract][Full Text] [Related]
20. Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S20-7. PubMed ID: 20824236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]